Summit, which is developing novel treatments for a genetic disorder and a bacterial infection, filed on Friday with the SEC to raise up to $40 million in an initial public offering.
The Abingdon, United Kingdom-based company, which was founded in 2003, plans to list on the NASDAQ under the symbol SMMT. Summit initially filed confidentially on December 4, 2014. JMP Securities and Oppenheimer & Co. are the joint bookrunners on the deal. No pricing terms were disclosed.
